http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2183755-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_56ee5285e8e8edccb061046ff20da7a6
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-183
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-49
classificationIPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-49
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-12
filingDate 1995-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f4db6a2b76ca20388667b349dd4c0ec6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2046319458a716a01764f549d73b5257
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6cfc979db613a9c0386eb8d95c484d07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_36c73e0996e906d60331ee77ac549e9e
publicationDate 1995-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CA-2183755-A1
titleOfInvention Pharmaceutical preparation containing plasminogen activators
abstract The invention relates to pharmaceutical prepara-tions containing plasminogen activators, sugars and tranex-amic acid, in the form of a lyophilisate or an injection or infusion solution. In particular, the preparations con-tain a sugar, phosphate buffer, tranexamic acid as well as a surfactant and the liquid solutions preferably have a pH value of 5.5-6.5.
priorityDate 1994-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5526
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419504209

Total number of triples: 32.